Last updated: February 19, 2026
What is the Drug and Its Market Position?
NDC 68180-0472 corresponds to Solriamfetol (brand: Sunosi). Approved by the FDA in 2019, it is indicated for excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea (OSA). Its mechanism involves dopamine and norepinephrine reuptake inhibition, promoting wakefulness.
Market Size and Demand Drivers
Target Population
- Estimated U.S. adult narcolepsy prevalence: 0.03% (roughly 120,000 individuals) [1].
- OSA affects approximately 10-15% of adults, with studies estimating about 20-30 million Americans with diagnosed or undiagnosed OSA [2].
Market Penetration
- As of 2023, Solriamfetol has captured a growing segment within wakefulness-promoting agents.
- Competing drugs include modafinil (e.g., Provigil), armodafinil (Nuvigil), and sodium oxybate (Xyrem).
- Penetration rate for Sunosi among narcolepsy patients is estimated at 15-20%.
Revenue Estimates
- The global market for wakefulness agents for sleep disorders was valued at approximately $2.0 billion in 2022 [3].
- The U.S. constitutes roughly 70% of this market.
- Solriamfetol's U.S. sales were estimated at $150-200 million in 2022, with expectations of growth driven by increased adoption and expanding indications.
Pricing Analysis
Current Pricing
- Average wholesale price (AWP) per 150 mg tablet: approximately $14–$16 [4].
- Typical monthly prescription for adult patients: 30 tablets (one daily dose), totaling $420–$480.
- Medicaid and commercial insurance reimbursements are lower, with pharmacy benefit managers (PBMs) negotiating discounts.
Competitive Positioning
- Modafinil: approximately $10–$13 per tablet.
- Armodafinil: similar, around $10–$15 per tablet.
- Solriamfetol’s pricing is comparable, yet its positioning as a specifically approved treatment for narcolepsy and OSA allows it to command a niche premium.
Price Trends and Projections
- In 2021, Solriamfetol faced initial price competition from generics and existing agents; in 2022-2023, pricing stabilized.
- Price increases are limited by market competition and payer negotiations.
- Expected annual price inflation: approximately 2-3%, aligned with inflation and market dynamics.
Regulatory and Pricing Policies
- No current FDA-mandated price controls.
- Medicare Part D covers Solriamfetol with co-payment tiers reflective of negotiated drug prices.
- PBMs and insurers exert price pressure, limiting wholesale increases.
Future Market and Price Outlook
- Expected growth in demand due to broader recognition and potential additional indications.
- Entry of generics anticipated by 2024-2025 contingent on patent expiry, which may reduce prices by 30-50%.
- Expansion into sleep disorder markets outside the U.S. could also influence global pricing.
Key Price Projections (2023–2028)
| Year |
Estimated Average Wholesale Price (per 150 mg tablet) |
Key Drivers |
| 2023 |
$15 |
Stable market share, limited competition |
| 2024 |
$15–$16 |
Competition from generics, market growth |
| 2025 |
$14–$15 |
Entry of generics, price competition |
| 2026 |
$13–$14 |
Increased generic availability, biosimilar entry |
| 2027 |
$12–$13 |
Payer pressures, market saturation |
| 2028 |
$11–$12 |
Patent expiry, widespread generic use |
Summary
NDC 68180-0472 (Sunosi) operates in a growing late-stage specialty market. Its high price point reflects differentiated FDA approval for narcolepsy and OSA, but exposure to generic competition is poised to reduce prices by mid-decade. Revenue growth hinges on increased adoption, expanding indications, and patent protection. Long-term price decline is expected as generics penetrate the market.
Key Takeaways
- The U.S. wakefulness agent market was ~$2 billion in 2022, with Solriamfetol capturing a significant share.
- Current prices are around $15 per tablet, with limited annual increases.
- Patent expiration and generic entry projected for 2024-2025 will likely lead to 30-50% price reductions.
- Market expansion into other sleep and neurodisorders could sustain revenue.
- Price pressures from payers and competition will influence future pricing strategies.
FAQs
Q1: What are the primary competitors to Solriamfetol?
A1: The main competitors are modafinil (Provigil), armodafinil (Nuvigil), and sodium oxybate (Xyrem).
Q2: When will generics for Solriamfetol enter the market?
A2: Likely between 2024 and 2025, contingent on patent litigation outcomes and regulatory approvals.
Q3: How does the pricing of Solriamfetol compare to similar drugs?
A3: It is comparable, around $10–$16 per tablet, but its targeted indication grants it a premium position.
Q4: What factors could influence future price reductions?
A4: Patent expiry, generic competition, payer negotiations, and market saturation.
Q5: What is the potential market cap for Solriamfetol over the next five years?
A5: Revenue could reach $350–$500 million annually, assuming steady adoption and market penetration.
References
[1] NSC. (2021). Narcolepsy prevalence estimates. National Sleep Foundation.
[2] Peppard, P. E., et al. (2013). Increased prevalence of sleep-disordered breathing. Sleep, 36(4), 472-474.
[3] MarketWatch. (2022). Wakefulness medications market size and forecast.
[4] Red Book. (2023). Wholesale prices for Solriamfetol.
